Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713204 | 1.00 | KCNH2 (0.39) | KCNH2ESR2ESR1LMNAACE | |
| SCHEMBL4759457 | 1.00 | KCNH2 (0.39) | KCNH2ESR2ESR1LMNAACE | |
| SCHEMBL2712967 | 1.00 | KCNH2 (0.39) | KCNH2ESR2ESR1LMNAACE | |
| SCHEMBL20835720 | 0.87 | FFAR2 (0.42) | KCNH2ACEFFAR2 | |
| SCHEMBL22534056 | 0.87 | ACE (0.42) | ESR2ESR1ACEMMEFFAR2 | |
| SCHEMBL2839895 | 0.79 | KCNH2 (0.50) | KCNH2FFAR2 | |
| SCHEMBL22546664 | 0.79 | KCNH2 (0.39) | KCNH2ESR2LMNAPDE5A | |
| SCHEMBL839485 | 0.79 | KCNH2 (0.39) | KCNH2ESR2LMNAPDE5A | |
| SCHEMBL841008 | 0.79 | KCNH2 (0.39) | KCNH2ESR2LMNAPDE5A | |
| SCHEMBL310430 | 0.79 | KCNH2 (0.39) | KCNH2ESR2LMNAPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177426-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN MA INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3953329-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Biogen MA Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210485-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN MA INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-1934177-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318530-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | HCRTR1, TACR2, CNR1 | KCNH2 7/4885ESR2 1570/4885ESR1 1354/4885 |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | KCNH2 7/4885ESR2 1103/4885ESR1 2206/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | KCNH2 3313/4885ESR2 1471/4885ESR1 3128/4885 |
| US-20220177426-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CPS1, PCCA, ALDH18A1 | KCNH2 774/4885ESR2 3973/4885ESR1 4601/4885 |
| US-20080280969-A1 | Novel Compounds | CYP11B2, CYP46A1, SLC10A1 | KCNH2 1998/4885ESR2 758/4885ESR1 1569/4885 |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | SCN5A, SCN1A, SCN7A | KCNH2 58/4885ESR2 3735/4885ESR1 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.